Decoding the anticancer activity of VO-clioquinol compound: the mechanism of action and cell death pathways in human...

Area of Science:

• Biochemistry
• Molecular Biology
• Medicinal Chemistry

Background:

• Vanadium compounds are emerging as non-platinum metal anticancer drugs.
• Identifying molecular targets and understanding cell signaling pathways are crucial for developing novel metallodrugs.
• Limited research exists on the specific cell signaling alterations induced by vanadium compounds.

Purpose of the Study:

• To investigate the antitumor properties of the oxovanadium(IV) complex VO(CQ)2.
• To identify novel molecular targets by analyzing protein expression changes in human osteosarcoma cells (MG-63).
• To elucidate the effects of VO(CQ)2 on intracellular signaling pathways.

Main Methods:

• Proteomic analysis of 224 proteins to identify differential expression.
• Production of human recombinant AKT1 kinase using an in vitro transcription/translation (IVTT) system.
• Evaluation of changes in AKT1 tyrosine phosphorylation levels upon treatment with VO(CQ)2.

Main Results:

• VO(CQ)2 demonstrated antitumor properties against MG-63 cells.
• Significant alterations in protein expression were observed, including upregulation of caspases (CASP3, CASP6, CASP7, CASP10, CASP11), Bcl-x, and DAPK, and downregulation of PKB/AKT and DIABLO.
• Signaling pathways involving PKC and AP2 families were identified as altered.
• A 2-fold decrease in AKT1 expression was observed at 10 μM concentration after 6 hours.

Conclusions:

• The oxovanadium(IV) complex VO(CQ)2 exhibits significant antitumor activity.
• VO(CQ)2 modulates critical cell signaling pathways and protein expression, highlighting its potential as a novel anticancer metallodrug.
• The study identifies potential novel molecular targets and provides insights into the mechanism of action for vanadium-based anticancer agents.